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Cyclophosphamide is an alkylating agent developed in the 1960s for the use in 
treatment of cancerous diseases. Since its introduction, it has manifested various 
spectra of effects. Of uttermost importance are the impacts cyclophosphamide has on 
the hematopoietic system housed in the bone marrow of femoral and other bones. 
Hematopoiesis is a complex process which has been extensively studied for decades. 
The more it is known about the niches the hematopoietic stem cells occupy as well as 
of their life cycle, the more it is possible to design functional therapy for its 
malignancies and improve the survival rates. The effects of cyclophosphamide 
administration on hematopoietic system are divided into three major cathegories: 
myeloablation and myelosuppression, immunosuppression, and mobilisation of 
hematopoietic stem cells into the peripheral blood. The immunosuppression is 
achieved by systematic depletion of progenitors differentiating into lecocytes. 
Induced neutropenia and lymphopenia allow for management of autoimmune 
diseases and preservation of transplants. Mobilisation, a process opposite to stem cell 
homing, seems to be dependent on disruption of cellular adhesion (CRXCR4/SDF-1, 
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Cyklofosfamid je alkylační činidlo vyrobené v šedesátých letech minulého století za 
účelem použití v protirakovinné terapii. Od svého uvedení manifestoval široké 
spektrum účinků. Velkou pozornost si zaslouží zejména účinky, které cyklofosfamid 
má na krvetvorbu, jež je lokalizována v dřeni stehenních a dalších kostí. Krvetvorba 
je složitý proces, jehož výzkum se odehrává už řadu desetiletí. Čím více je toho 
známo o takzvaných nikách okupovaných hematopoetickými kmenovými buňkami, 
jakožto i o jejich životním cyklu, tím snadněji se dá vyvíjet účinná terapie proti 
malignitám, což ve výsledku vede i k navýšení počtu přeživších pacientů. Dopad 
cyklofosfamidu na krvetvorbu se dá shrnout třemi hlavními pojmy: myeloablace a 
myelosuprese, imunosuprese, mobilizace hematopoetických kmenových buněk do 
periferní krve. Imunosuprese je dosaženo systematickou deplecí progenitorových 
buněk diferencujících se do bílých krvinek. Navozená neutropenie a lymfopenie 
umožňují zmírnění (i když většinou nikoliv vyléčení) autoimunitních chorob a 
zabránění odmítnutí štěpu po allotransplantaci. Mobilizace, proces opačný 
k takzvanému „homingu“ krvetvorných kmenových buněk, se zdá být závislou 
především na eliminaci buněčné adheze (CRXCR4/SDF-1; VCAM-1/VLA-4) 
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 N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide 
(cyclophosphamide) has been used in humane as well as veterinary medicine for 
great many years (Henry et al, 1994). It is a potent drug belonging into a family of 
alkylating agents called oxazaphosphorines that have numerous effects. They are:  
mutagenic, teratogenic, carcinogenic, immunosuppressive and antineoplastic to 
name just a few (Kenney et al, 2001). Cyclophosphamide is currently in use 
worldwide mainly in the treatment of several kinds of cancerous diseases, usually in 
combination with several other chemotherapeutic agents. It is quite versatile as far as 
its use in the clinical setting is concerned.  
 Among its most important effects are those cyclophosphamide has on 
hematopoiesis. Not only is it able to cause myeloablation and immunosuppression, it 
is also capable of mobilising hematopoietic stem cells into the peripheral blood and 
thus enables their use for autotransplantation in patients with severe hematologic 
malignancies and immune malignancies. 
 This thesis aims to explore and put into perspective the knowledge that has 
been accumulated and refined since the first preparation of cyclophosphamide some 





2. Cyclophosphamide Metabolism 
Cyclophosphamide in itself is a harmless substance (a prodrug) that needs to be 
bioactivated to acquire its cytotoxic properties (see Figures 4 and 5). 
 
2.1. Key Enzymes 
2.1.1. Cytochrome P450 
Cytochrome P450 (CYP) is a name given to a group of enzymes belonging to 
the class of oxidoreductases. The P450 part of the name is derived from the fact that 
during a spectroscopic analysis they demonstrate the highest absorbance when the 
analytic beam of light has the wavelength of 450 nanometres.  
These enzymes can been found throughout eukaryotic organisms and in some 
bacteria (generally those, which use hydrocarbons as a source of carbon as well as 
energy). In mammals they are included in a wide spectrum of metabolic pathways – 
steroidogenesis, metabolism of vitamins A and D, eicosanoid metabolism, 
transformation of xenobiotics (de Montellano, 2005). Some of them possess several 
functions and respond to the presence of a wider range of substrates. Only a handful 
of human cytochrome P450s are capable of transformation of xenobiotics, but all of 
those are capable of processing an endogenous substrate, albeit usually with lower 
specificity and/or metabolic rate. 
CYPs are cysteinato-heme proteins (see Figure 1) which in mammals vary in 
expression according to the species, localisation, environment – some CYPs are 
expressed constitutively, others are inducible – age and even gender of the 
individual. The majority of CYPs are in occurrence in the liver. They are 
membrane-bound proteins which occur predominantly in the endoplasmic 




Figure 1. Prosthetic of cysteinato-heme enzymes: an iron-(III) protoporphyrin-IX 
linked with a proximal cysteine ligand. (reproduced from Meunier et al, 2004) 
 
Cytochrome P450s have been identified as a crucial component of the 
cyclophosphamide metabolic pathway, as it is these enzymes that enable 
cyclophosphamide’s bioactivation (Pass et al, 2005; Ren et al, 1997). 
Cyclophosphamide in the liver is activated by a group of CYP isoenzymes by means 
of hydroxylation on its C-4 atom. This reaction yields 4-hydroxycyclophosphamide 
and its tautomeric form aldophosphamide, which are at equilibrium.  
CYPs are often referred to as monooxygenases because they use molecular 
oxygen in the oxidation reactions they catalyse, and incorporate only one of its atoms 
into the substrate that is being catalysed. The other oxygen atom is reduced to water 
with two electrons provided by NAD(P)H via a reductase (Equation 1). 
 
 
RH + O2 + 2H+ + 2e- → ROH + H2O 




The enzymes thought to possess the greatest potential with regards to 
cyclophosphamide metabolism have been identified as: CYP2B6, CYP2A6, CYP2C9 
and CYP3A4 (Roy et al, 1999). While the majority of the applied dose of 
cyclophosphamide follows the route of 4-hydroxylation and activation, a smaller 
portion can follow another metabolic pathway – N-dechloroethylation and 
subsequent formation of inactive and neurotoxic chloroacetaldehyde. CYP3A4 
proved to be the most prolific in this alternative metabolism (Huang et al, 2000). 
Unfortunately, there is a substantial genetic polymorphism in CYPs, leading to 
several abnormalities in the metabolism of cyclophosphamide – such as lower 
substrate specificity, a lower metabolic rate – in some individuals, which may result 
in the patient being less responsive to treatment by the drug, and other adverse 
situations (Griskevicius et al, 2003; Xie et al, 2003).  
Moreover, cyclophosphamide is often used in combination chemotherapy 
during which several chemicals are co-administered, therefore possible drug-drug 
interactions have to be carefully evaluated. For example 
triethylenethiophosphoramide (thioTEPA) – a common antineoplastic agent – is 
responsible for specific uncompetitive inhibition of CYP 2B6, and thus interferes with 
the conversion of cyclophosphamide to 4-hydroxycyclophosphamide (Harleton et al, 
2004; Rae et al, 2002). Even cyclophosphamide itself regulates its own metabolism by 
induction of CYPs with subsequent increase in 4-hydroxylation rate (Chang et al, 
1997); on the other hand acrolein that is produced further along the activation 
pathway is thought to be responsible for inhibiting cyclophosphamide metabolism 
by interacting with both CYPs and the CYP reductase (LeBlanc & Waxman, 1990). 
 
2.1.2. CYP Reductase 
Cytochrome P450 reductase (also known as cytochrome c reductase) is a 
protein localised on the cytosolic face of the endoplasmic reticulum, and is most 
abundant in hepatocytes (Phillips & Langdon, 1962). It is safely anchored into the 
membrane of the endoplasmic reticulum by a sequence of about sixty amino acids. 
The cytosolic part is comprised of two domains. The first one has two binding sites 
for NADPH and uses a FAD molecule as a cofactor, while the other one employs a 
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FMN (flavin mononucleotide) molecule as its cofactor and is responsible for the 
contact with a CYP molecule. The tertiary structure of the enzyme is highly 
conserved, indicating its importance. 
The reductase shuttles electrons to the CYP in several steps. Upon binding 
NADPH the FAD-domain is reduced by two hydride ions simultaneously. In the 
next step, the electrons are channelled to the FMN-domain in sequence, and finally to 
the CYP (Vermilion et al, 1981). Two conformational states of the reductase have 
been described – the “open” state is compatible with FMN-heme electron transfer, 
while the “closed” state allows FAD-FMN electron transfer (Fig. 2) (Ellis et al, 2009).  
 
 
Figure 2. The open (left) and closed (right) conformations of the CYP reductase. The 
FMN domain is shown in blue, the linker domain in purple and the FAD domain in 
green colour. The cofactors are shown: FMN – yellow, FAD – red, NADPH – blue 
(reproduced from Ellis et al, 2009). 
 
Despite having two binding sites for NADPH, only one of them is catalytic. 
Simultaneous binding of two molecules of NADPH actually attenuates the reaction, 
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most probably by interfering with the release of NADP+ from the catalytic site (de 
Montellano, 2005).  
The diflavin reductase is vital for monooxygenation reactions of CYPs because 
it provides the electrons necessary for reduction of the CYP in question, and 
subsequently the reduction of an oxygen atom to water. An experimental knockout 
mouse strain deficient in expression of hepatic CYP reductase (Hepatic Cytochrome 
P450 Null – HNR) – to the extent of expressing less than 1 % of the amount of the 
enzyme produced by wild-type mice – in which has the conversion of 
cyclophosphamide to 4-hydroxyphosphamide been significantly halted, and its 
half-life in plasma dramatically increased, have been used to study the importance of 
the CYP reductase for CYP-facilitated drug metabolism (Pass et al, 2005). Despite 
having virtually no hepatic CYP reductase activity, the bioactivation of 
cyclophosphamide still takes place owing to extra-hepatic activation, but the amount 
of 4-hydroxycyclophosphamide produced is correspondingly lowered. The 
extra-hepatic bioactivation of cyclophosphamide has been demonstrated on another 
mouse strain – the CL-LCN (CYP reductase-low, liver- CYP reductase-null) mice (Gu 
et al, 2007). 
 
2.2. Activation Pathway 
2.2.1. 4-hydroxycyclophosphamide 
 A tautomer of aldophosphamide, 4-hydroxyphosphamide has been shown to 
possess little cytotoxic potential and is therefore not considered to be a therapeutic 
metabolite of cyclophosphamide. Nevertheless, it does have an important function as 
this is the form in which the drug enters target cells, and tautomerises to 
aldophosphamide, which then undergoes further metabolic processing leading to the 
final therapeutic product. It is presumed that 4-hydroxycyclophosphamide travels to 
its final destination bound to the red blood cells. This notion is largely supported by 
the findings of higher concentrations of activated oxazaphosphorines in the 




2.2.2. Spontaneous Reaction of Aldophosphamide 
Aldophosphamide that is transported to target tissues by the blood circulatory 
system undergoes a non-enzymatic elimination to form phosphoramide mustard and 
acrolein, former of which is an alkylating agent that forms intra- as well as 
interstrand cross-links in the DNA and protein-DNA cross-links. Such an 
intervention to the integrity of the DNA constitutes a significant damage to the cell 
and may lead to its death by either apoptosis or necrosis – that is the basic principle 
of cyclophosphamide and related substances’ (ifosfamide, trofosfamide) therapeutic 
effect. On the other hand, acrolein is a highly nephrotoxic and neurotoxic by-product 
of the reaction. Cytotoxic properties of the compound cause a disease of the urinary 
bladder called haemorrhagic cystitis (Lawrence et al, 1975). 
 Even though the reaction does not require a catalyst, it has been established 
that human serum albumin speeds up the process (Kwon et al, 1987). However, the 
phosphoramide mustard generated in the blood does not pose a significant threat to 
tissues as it is mostly ionised (at physiological pH) which is the underlying reason 
for its decreased ability to pass through the plasma membrane of cells.  
In addition to the spontaneous reaction aldophosphamide can also serve as a 
substrate for an aldehyde dehydrogenase which catalyses its oxidation to the inactive 
carboxyphosphamide by molecular oxygen. At the same time a superoxide anion 
belonging to the group of reactive oxygen species (ROS) is generated. It has been 
suggested that upregulation of the enzyme contributes to cyclophosphamide 
resistance (Manthey et al, 1990). 
 
2.2.3. Acrolein 
 In spite of contributing to the cytotoxic properties of cyclophosphamide, the 
generation of acrolein quantitatively equal to phosphoramide mustard is mostly 
undesirable due to its role in the development of haemorrhagic cystitis and 
neurotoxicity. Acrolein produced by β-elimination from aldophosphamide causes 
single-strand breaks in the DNA and readily binds to cellular proteins (Crook et al, 
1986). From the fact that it has been known to deplete the cellular glutathione has 
been derived the practice of co-administration of protective drugs which include 
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sulphhydryl-containing compounds such as mesna (Figure 3), which allow for its 
safe elimination from the body.  
Acrolein is at least on order of magnitude more effective in depletion of 
glutathione than phosphoramide mustard, therefore agents responsible for 
protection again acrolein toxicity can be used without halting the curative effect of 
cyclophosphamide (Gurtoo et al, 1981). 
 
 
Figure 3. The structure of mesna. 
 
2.2.4. Phosphoramide Mustard 
 The phosphoramide mustard’s potential to cause damage to cells by alkylation 
of their nucleic acids lies within its electrophilic aziridinium group which naturally 
seeks a nucleophilic partner to react with. The N-7 of guanines has proven to be a 
favoured site for alkylation, especially if they are flanked by more guanines. As the 
mustard possesses two functional groups, it interconnects two reaction sites, thus 
forming the inter- and intrastrand (most often between directly adjacent bases) 
crosslinks as well as nucleic acid-protein crosslinks (Kohn et al, 1987).  
 Cyclophosphamide metabolism has been extensively studied in mice. There is 
a major difference between human and murine metabolisms that has to be accounted 
for when applying murine data into clinical practice. While there are no active 
metabolites detectable in murine blood as soon as one hour after dose administration 
(personal communication with RNDr. Luděk Šefc, CSc.), the build-up of active 
metabolites and clearance in humans is slower and happens in a space of several 
hours. Importantly, there does not seem to be a difference between oral and 
intravenous routes of administration, which means patients can be offered the more 
comfortable oral treatment without compromising the therapeutic outcome (Struck et 
al, 1987).  








Figure 4. Metabolism of cyclophosphamide. Vertically: activation of 
cyclophosphamide; horizontally: inactivation pathways (reproduced from de Jonge 






Figure 5. Metabolic pathways of cyclophosphamide in a target cell.  
(source: http://www.pharmgkb.org/views/pathway/PA2034.pdf - reproduced 








Hematopoiesis is a process during which hematopoietic stem cells (HSCs) 
maintain their numbers, and produce a cohort of terminally differentiated mature 
blood cells. During the foetal development hematopoietic activity can be observed in 
the liver as well as the spleen, but the bone marrow is the only site that supports 
hematopoiesis after the birth and throughout adulthood. Indeed, extramedullary 
(occurring outside the bone marrow compartment) hematopoiesis is widely 
recognised as a sign of a disease and/or a direct consequence of 
chemotherapeutically or by irradiation impaired hematopoietic capacity of the bone 
marrow. In these cases, extramedullary hematopoiesis serves as a mechanism for 
compensation of the lost medullary hematopoiesis (Singer et al, 2004). 
Splenectomised mice recover more slowly than controls after 
cyclophosphamide-induced hematosuppression (Wang et al, 2009).  
 HSCs differ from the embryonic stem cells in one important aspect – they 
cannot give rise to the whole spectrum of cell types occurring in the body. The HSC 
is a member of a family of tissue-specific stem cell, among which are also counted 
neural stem cells, cord blood stem cell from the umbilical cord, bone marrow stromal 
stem cells. As the name “tissue-specific stem cells” suggests, these stem cells are only 
used to replenish specific types of tissues. They are multipotent.  
 Special places within the bone marrow housing HSCs have been postulated. 
These are called niches, and currently two distinct types of them are recognised. The 
niche is a place in which a HSC receives signals that regulate its function or induce 
dormancy, be it by soluble metabolites, cytokines or direct cell-to-cell contact with 
non-HSCs forming the niche. Each heamatopoietic stem cell can upon division follow 
either of two routes – (a) maturation through sequential loss of potency and exit from 
the niche (b)staying in place and continuing with the production of its own clones or 






Figure 6. A simplified overview of hematopoiesis. The self-renewal capacity of HSCs 
is indicated by the arrow. The gradual loss of colouring indicates increased lineage 
commitment (Gerrits et al, 2008).  
 
 Of the two aforementioned types of niches, the endosteal niche seems to be the 
place where dormant and slow cycling HSCs with the biggest potential for 
self-renewal are located. The niche comprises cells of mesenchymal origin which 
directly interact with the HSCs. The HSCs residing in this niche are called long-term 
hematopoietic stem cells (LT-HSCs), which reflects their ability contribute to 
hematopoiesis over a long period of time or even a lifetime.  
 The microenvironment which is typical for this niche is made up by stromal 
cells – osteoblasts, adipocytes, endothelial cells and fibroblasts, and the endothelium 
is in direct contact with the calcified bone matter. A population of specialised 
N-cadherin-expressing osteoblasts (SNOs) has been found to be absolutely essential 
for HSCs. These SNOs communicate with the HSCs through homotypic N-cadherin 
interactions (Zhang et al, 2003). Experiments with mice that had the numbers of bone 
marrow osteoblasts dramatically lowered (conditional or permanent ablation) 
showed that these mice had also insufficient numbers of LT-HSCs and, as a direct 
consequence of that, substantial decrease of lymphoid, erythroid and myeloid 
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progenitors (including osteoclast progenitors) was observed (Visnjic et al, 2004). The 
interactions in the niche do not seem to be only one-way, as it has been noted that 
HSCs drive mesenchymal cells toward osteoblastic lineage when they are grown in a 
co-culture.  
 The other distinct type of niche is a vascular one. This niche is supposedly 
inhabited by short-term hematopoietic stem cells (ST-HSCs) that have migrated here 
from the endosteal niche. As is to be expected, the architecture and overall 
microenvironment of the niche differs from the endosteal one. In the vascular niche 
the HSCs are in contact with the fenestrated endothelium of capillaries, which 
enables them to closely monitor concentrations of molecules dissolved in blood. 
Therefore a swift response could be mounted should the situation require it (Yang et 
al, 2005). 
 The ST-HSCs give rise to a progeny of multipotent progenitor cells (MPPs). 
The MPPs can support generation of mature blood cells of all types, but lack the 
ability to self-renew. The ST-HSCs have in contrast to the LT-HSCs a significantly 
lower capacity for self-renewal and consequently can single-handedly support 
hematopoiesis for several weeks only, which is why LT-HSCs are by far better suited 
for hematopoietic stem cell transplantations. HSCs transplantations are typically 
carried out in an attempt to correct aberrant hematopoiesis, therefore a long-term 
solution to the patient’s problems is desirable.  
 Hematopoiesis is complex process, regulation of which is not yet fully 
clarified, even though a great mass of processes has been studied and our knowledge 
of it is quite extensive. Apart from direct cell contact and communication between 
endosteal and vascular niches, cytokines, the endocrine system (regulation of 
erythropoiesis by erythropoietin) and metabolic factors (such as varied oxygen 
levels) all take part in it. For example granulocyte colony-stimulating factor (G-CSF), 
granulocyte-monocyte colony-stimulating factor (GM-CSF), macrophage 
colony-stimulating factor (M-CSF) are all powerful stimulators driving hematopoietic 
progenitors to differentiation in vitro. However, in vivo deficiencies in these factors do 
not necessarily lead to a certain cell type being completely absent (Lieschke et al, 
1994). It seems that these factors do not solely provide lineage-specific signals for 
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differentiation of HSCs and multipotent progenitors, but rather stimulate the 
survival/expansion of progenitors, and play a greater role at the terminal maturation 
stages. On the other hand, interleukin-7 (IL-7) is utterly irreplaceable when it comes 
to B-cell differentiation. Mice deficient in IL-7 still do produce common lymphoid 
progenitor cells (CLPs). B-cell production, however, is blocked. The IL-7 regulates the 
immunoglobulin gene rearrangement once the cell has committed to the B-cell 
lineage and entered the pro-B-cell stage (von Freeden-Jeffry et al, 1995). 
 Hematopoietic stem cells are seldom to be seen circulating in the blood 
(Abkowitz et al, 2003). During the period of embryonic development they migrate 
from liver and “home” into the bone marrow, establish a stable population in there, 
and produce high levels of immature and maturing cells of all lineages. The HSCs 
can be encountered in blood during leukemias and various inflammatory conditions, 
after injection of granulocyte colony-stimulating factor (G-CSF), and after 
administration of cyclophosphamide (Szumilas et al, 2005). 
 
3.1. Cyclophosphamide Effects on Hematopoiesis 
3.1.1. Myeloablation, Myelosuppression and Immunosuppresion 
Cyclophosphamide was developed in the 1960s with the objective to create a 
powerful new antineoplastic agent that would be maximally efficient in battling 
cancerous growth and, at the same time, be as little toxic to the patients’ healthy 
tissues as possible. Although it has turned out to be pretty competent in the first 
field, problems connected to its overall toxicity do occur. As it is the case for virtually 
any antineoplastic drug and radiation therapy, the regimen affects fast-dividing cells 
the most – probably due to the DNA being more easily accessible when the nuclear 
envelope dissolves during mitosis – unfortunately neoplastic tissues are not the only 
ones which divide fairly quickly. The hematopoietic system housed in the bone 
marrow is another great target for anti-cancer therapeutics, with hematopoietic 
progenitor cells being the most vulnerable (DeWys et al, 1970; Valeriote et al, 1968). 
Severe Myelosuppression is to this day one of the key dose-limiting aspects of 
cyclophosphamide administration in the clinical setting, and might even happen to 
be a reason for discontinuing chemotherapy in some patients (Presant & Klahr, 1977). 
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 Injury to the bone marrow by a cyclophosphamide-containing regimen of 
treatment usually leads to a pronounced decline in the granulocyte, lymphocyte, 
thrombocyte numbers (Fried & Johnson, 1968; Mosienko et al, 2002), and severe cases 
of anemia, which is in accordance with an observable decrease in bone marrow 
cellularity (Sefc et al, 2003). While the cases of developed anemia and 
thrombocytopenia can be confronted by administering blood and thrombocyte 
transfusions respectively, the transfusions are still just a way of minimising the 
damage without solving the underlying problem.  
 The most serious of all cytopenias induced by cyclophosphamide is 
neutropenia. Patients who see their neutrophil levels fall below the value 
of 100 cells/mm3 (severe neutropenia) are extremely prone to infection by pathogens 
such as Klebsiella pneumonie, and are incapable of initiating an efficient immune 
response against them. A concomitant administration of prophylactic antibiotic 
drugs is therefore required (Tjan-Heijnen et al, 2001). Treatment protocols also 
sometimes include G-CSF as it has been shown that it can reduce neutropenia 
(Neidhart et al, 1989). 
 In a stark contrast to the undesired chemotherapy-induced immunosuppression 
in cancer sufferers is the intentional prescription of cyclophosphamide which aims to 
achieve this result. Cyclophosphamide is a drug of choice for the management of 
some very severe immune disorders (Burt et al, 1998). Among these are systemic 
lupus erythematosus (Katsifis et al, 2002), systemic sclerosis; and cyclophosphamide 
is currently being tested as a promising therapy for autoimmune aplastic anemia 
patients (Brodsky et al, 2004; Brodsky et al, 2001). 
 Yet another situation in which immunosuppression by cyclophosphamide is 
desirable is the pre-transplantation conditioning of the intended host (Kapoor et al, 
1981; Litzow et al, 2002). Elimination of host alloreactive lymphocytes serves 
as a prevention of the rejection of a transplant (Aversa et al, 1999). Moreover, 
high-dose cyclophosphamide seems to be quite efficient even in the capacity of 
single-agent prophylaxis against both acute and chronic graft-versus-host disease 
(Luznik et al).  
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 The myelosuppressive effect has been attributed to cyclophosphamide right 
from the very beginning of its use in cancer therapy. Mice that were subjected to 
cyclophosphamide in doses equivalent of bone marrow-injury causing γ-irradiation 
in early studies had been found to develop a corresponding response of a trauma 
and subsequent improvement. What was more of an interest was the fact that murine 
bone marrow and peripheral blood cell count recovered more swiftly after 
cyclophosphamide regimen. Moreover an overshot in reticulocytes could be 
observed – so-called rebound reticulocytosis (Valeriote et al, 1968). While the 
myelotoxic effect of cyclophosphamide has an unquestionably great negative impact 
on experimental models (mostly mice) and human patients both, it is nonetheless 
only temporary and can be weathered with supportive therapy.  
 The transient nature of cyclophosphamide-induced myelosuppression is 
attributable to its mode of action. While rapidly proliferating hematopoietic 
progenitor cells are hit with full force, slow-cycling hematopoietic stem cells are 
more resistant to the drug. The conservation of HSCs is intrinsic for hematopoietic 
reconstitution. Cyclophosphamide regimens need to be established so that HSCs 
have enough time to replenish the pool of HPCs. During the period of hematopoietic 
reconstitution, when the HSCs divide rapidly to compensate the loss of progenitor 
and mature blood cells, are even these cells susceptible to damage by 
cyclophosphamide, which is counterproductive in regimens where the HSCs are not 
the intended targets.  
 In recent years, various studies have been focused on eliminating, or at least 
decreasing, the hematologic toxicity of chemotherapeutic agents. Notably 
macrophage inflammatory protein-1 alpha (MIP-1α) piqued researchers’ interest due 
to its ability to cause cell-cycle arrest, which could serve as protection for HPCs. 
However, this chemokine naturally polymerises in extremely low concentrations 
(>20 ng/ml), which consequently renders it inactive. Retaining its native form by 
means of organic solvents was not a suitable option for patient therapy. A 
recombinant protein with significantly lowered polymerising tendencies has been 
developed. While it cannot prevent cyclophosphamide-induced neutropenia or its 
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severity, it seems to speed up the recovery process, which is promising for the future 
(Gilmore et al, 1999; Marshall et al, 1997). 
 Meanwhile cyclophosphamide serves as an effective means of making murine 
models immunosuppressed, which is very useful for exact evaluation of the efficacy 
of antibiotics (Zuluaga et al, 2006). 
 
3.1.2. Mobilisation of Hematopoietic Stem Cells 
 The list of effects cyclophosphamide has on hematopoiesis by no means ends at 
myelosuppression and immunosuppression. Another important outcome of 
cyclophosphamide administration is the mobilisation of hematopoietic stem and 
progenitor cells (sorted according to the expression of surface CD34+ marker) into the 
peripheral blood. This is widely used in clinical practice for mobilisation of CD34+ 
cells into the peripheral blood, from where they can be collected by a process of 
apheresis and further used for autologous transplantations (Rosen et al, 2000). 
Mobilisation protocols do not usually employ cyclophosphamide as the sole agent as 
it has been demonstrated that significantly higher numbers of progenitors are 
collected when G-CSF or GM-CSF are included in the regimen (Caporali et al, 2001). 
The aforementioned growth factors can also stimulate mobilisation singlehandedly 
(Abkowitz et al, 2003), but their combination with chemotherapy is also beneficial in 
terms of yield. Nevertheless, cyclophosphamide is not included in mobilisation 
regimens in healthy donors due to its toxic properties, because it would simply not 
be ethical to impose those on healthy individuals.  
 The process of release of HSCs and HPCs from the bone marrow into the 
peripheral blood has not yet been completely elucidated, although some important 
discoveries have been made. Being de facto the direct opposite of homing, the 
attention of researches has been turned to adhesive molecular pairs such as very late 
antigen 4 (VLA-4) and vascular cell adhesion molecule-1 [VCAM-1 (Kikuta et al, 
2000)]; and chemokines and their receptors such as stromal cell-derived factor 1 
(SDF-1/CXCL12) and its receptor CXCR4. The evidence for the importance of 
VLA-4/VCAM-1 stems from studies utilising anti-VLA-4 antibodies. The 
administration of VLA-4 antibodies leads to successful mobilisation of HSCs in 
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experimental animals (Papayannopoulou & Nakamoto, 1993). Neutralisation of 
VLA-4 also prevents homing of transplanted HSCs (Zanjani et al, 1999). 
 SDF-1 is highly expressed in the bone marrow, notably by the immature 
osteoblasts of the endosteal niche. The gradient of SDF-1 is deemed necessary for 
homing of CD34+ both in steady-state hematopoiesis and after transplantation into 
myeloablated hosts. CXCR4 is a membrane-bound receptor protein with seven 
transmembrane domains. It is linked to G-proteins and the signal cascade initiated 
upon interaction with SDF-1 may result for example in the reorganisation of actin 
cytoskeleton and formation of pseudopodia. SDF-1α induces phosphorylation of 
multiple adhesion proteins. The importance of SDF-1/CXCR4 axis for hematopoiesis 
has been demonstrated in vivo when knock-out mice lacking both molecules 
developed severe defects in B lymphopoiesis and myelopoiesis.  
 On the other hand, mobilisation can be induced in mice by artificial 
overexpression of SDF-1, as too high a concentration leads to desensitisation and 
internalisation/degradation of CXCR4 of the target cells and thus to their 
unresponsiveness to SDF-1 (Alsayed et al, 2007). This discovery was most important 
as it had been previously shown that chemotherapy tends to increase the levels of 
SDF-1 in the bone marrow, and yet cyclophosphamide does facilitate mobilisation, 
which naturally seemed contradictory. Moreover, so-called “poor mobilisers” in 
whom achievement of target numbers of collected CD34+ cells for autologous 
transplantations is problematic do express more SDF-1 at steady state than “good 
mobilisers” and healthy individuals (Gazitt & Liu, 2001). Even though mobilised 
HCSs express significantly less CXCR4 (Carion et al, 2003; Gazitt & Liu, 2001), they 
are able to home into the hosts bone marrow. This is attributed to chemokine and 
overall environment of the hosts circulatory system which promotes the production 
of new CXCR4 receptors on the cell surface.  
 It has been observed that rising numbers of hematopoietic progenitors in the 
peripheral blood are in direct correlation with increased levels of proteolytic 
enzymes in the bone marrow (Levesque et al, 2002). Matrix metalloproteinase 9 
(Carion et al, 2003), cathepsin G and leucocyte elastase all degrade the N-terminus of 
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SDF-1 in vitro which disallows binding to the receptor and results in the loss of its 
chemoattractant function.  
 AMD-3100 (also known as plerixafor) is a substance causing reversible 
inhibition of CXCR4 (Hendrix et al, 2000). When it is combined with G-CSF in human 
donors for mobilisation, the collected cells express higher levels of VLA-4, tend to 
migrate to SDF-1 better, and also show significantly better engraftment in 
NOD/SCID (non-obese diabetic/severe combined immunodeficiency) hosts. This 
example of crosstalk between chemokines and/or adhesion molecules is not the only 
of the kind, and much effort is currently being put into deciphering the relationship 
status of various chemokine/adhesion molecule interaction-induced responses of 





 Cyclophosphamide is an old drug put to new uses as we gradually discover 
how a human body works. Its precise metabolism and mode of action has long been 
a mystery, but decades of research are slowly heading to illumination of the 
principles. 
 It is now possible to fully appreciate how a polymorphism in a gene coding 
a particular enzyme influences the metabolism of the drug, and interpatient 
differences can be addressed. As the mankind sees the numbers of malignancies 
rising, it is most beneficial that cyclophosphamide’s mode of action is better 
understood than it used to be fifty years ago.  
 Its use in hematology has been extensively studied. Interestingly, 
cyclophosphamide can mimic both the impact of γ-irradiation and of the 
hematopoietic growth factor G-CSF depending on dosage, timing and genetic 
background of the subject. 
 In its capacity of mobilisation-inducing drug cyclophosphamide demonstrated 
quite similar tendencies to G-CSF – after its administration, bone marrow 
environment reacts by releasing stored neutrophil proteases which cleave molecules 
facilitating chemotaxis and adhesion to the bone marrow niche, thus enabling the 
egress of stem and progenitor cells into the peripheral blood. Among the affected 
molecular pairs studied in recent years are CXCR4 and its ligand SDF-1, and VLA-4 
with VCAM-1. These interactions cannot be viewed as isolated systems, as one 
stimulus can often influence the way another one is processed, and there is 
significant amount of cross-talk going on. More studies of these kinds of interactions 
are yet to come and will hopefully lead to improvement of clinical protocols and 
brighter outlook for patients with hematologic and immune malignancies, whose 
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